Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T)

Jonathan S. Cebon; Keith Flaherty; Jeffrey S. Weber; Kevin Kim; Jeffrey R. Infante; Adil Daud; Omid Hamid; Richard Kefford; Lynn Mara Schuchter; Jeffrey Alan Sosman; Mario Sznol; William Howard Sharfman; Rene Gonzalez; Miles Cameron Andrews; Roxana Stefania Dronca; Georgina Long; Shonda M. Little; Peng Sun; Kiran Patel; Robert R. McWilliams

doi:10.1200/jco.2013.31.15_suppl.9016

Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T)

Jonathan S. Cebon, Keith Flaherty, Jeffrey S. Weber, Kevin Kim, Jeffrey R. Infante, Adil Daud, Omid Hamid, Richard Kefford, Lynn Mara Schuchter, Jeffrey Alan Sosman, Mario Sznol, William Howard Sharfman, Rene Gonzalez, Miles Cameron Andrews, Roxana Stefania Dronca, Georgina Long, Shonda M. Little, Peng Sun, Kiran Patel, Robert R. McWilliams

Faculty of Medicine, Health and Human Sciences

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	9016-9016
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	31
Issue number	15 supplement
DOIs	https://doi.org/10.1200/jco.2013.31.15_suppl.9016
Publication status	Published - 20 May 2013
Event	Annual Meeting of the American Society of Clinical Oncology (ASCO) - Chicago, United States Duration: 31 May 2013 → 4 Jun 2013

Access to Document

10.1200/jco.2013.31.15_suppl.9016

Cite this

Cebon, J. S., Flaherty, K., Weber, J. S., Kim, K., Infante, J. R., Daud, A., Hamid, O., Kefford, R., Schuchter, L. M., Sosman, J. A., Sznol, M., Sharfman, W. H., Gonzalez, R., Andrews, M. C., Dronca, R. S., Long, G., Little, S. M., Sun, P., Patel, K., & McWilliams, R. R. (2013). Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T). Journal of Clinical Oncology, 31(15 supplement), 9016-9016. https://doi.org/10.1200/jco.2013.31.15_suppl.9016

Cebon, Jonathan S. ; Flaherty, Keith ; Weber, Jeffrey S. et al. / Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T). In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 15 supplement. pp. 9016-9016.

@article{62ff5894b857472d9f1f4afac2f13a5f,

title = "Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T)",

author = "Cebon, \{Jonathan S.\} and Keith Flaherty and Weber, \{Jeffrey S.\} and Kevin Kim and Infante, \{Jeffrey R.\} and Adil Daud and Omid Hamid and Richard Kefford and Schuchter, \{Lynn Mara\} and Sosman, \{Jeffrey Alan\} and Mario Sznol and Sharfman, \{William Howard\} and Rene Gonzalez and Andrews, \{Miles Cameron\} and Dronca, \{Roxana Stefania\} and Georgina Long and Little, \{Shonda M.\} and Peng Sun and Kiran Patel and McWilliams, \{Robert R.\}",

year = "2013",

month = may,

day = "20",

doi = "10.1200/jco.2013.31.15\_suppl.9016",

language = "English",

volume = "31",

pages = "9016--9016",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15 supplement",

note = "Annual Meeting of the American Society of Clinical Oncology (ASCO) ; Conference date: 31-05-2013 Through 04-06-2013",

}

Cebon, JS, Flaherty, K, Weber, JS, Kim, K, Infante, JR, Daud, A, Hamid, O, Kefford, R, Schuchter, LM, Sosman, JA, Sznol, M, Sharfman, WH, Gonzalez, R, Andrews, MC, Dronca, RS, Long, G, Little, SM, Sun, P, Patel, K & McWilliams, RR 2013, 'Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T)', Journal of Clinical Oncology, vol. 31, no. 15 supplement, pp. 9016-9016. https://doi.org/10.1200/jco.2013.31.15_suppl.9016

Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T). / Cebon, Jonathan S.; Flaherty, Keith; Weber, Jeffrey S. et al.
In: Journal of Clinical Oncology, Vol. 31, No. 15 supplement, 20.05.2013, p. 9016-9016.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T)

AU - Cebon, Jonathan S.

AU - Flaherty, Keith

AU - Weber, Jeffrey S.

AU - Kim, Kevin

AU - Infante, Jeffrey R.

AU - Daud, Adil

AU - Hamid, Omid

AU - Kefford, Richard

AU - Schuchter, Lynn Mara

AU - Sosman, Jeffrey Alan

AU - Sznol, Mario

AU - Sharfman, William Howard

AU - Gonzalez, Rene

AU - Andrews, Miles Cameron

AU - Dronca, Roxana Stefania

AU - Long, Georgina

AU - Little, Shonda M.

AU - Sun, Peng

AU - Patel, Kiran

AU - McWilliams, Robert R.

PY - 2013/5/20

Y1 - 2013/5/20

U2 - 10.1200/jco.2013.31.15_suppl.9016

DO - 10.1200/jco.2013.31.15_suppl.9016

M3 - Meeting abstract

SN - 0732-183X

VL - 31

SP - 9016

EP - 9016

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15 supplement

T2 - Annual Meeting of the American Society of Clinical Oncology (ASCO)

Y2 - 31 May 2013 through 4 June 2013

ER -

Cebon JS, Flaherty K, Weber JS, Kim K, Infante JR, Daud A et al. Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T). Journal of Clinical Oncology. 2013 May 20;31(15 supplement):9016-9016. doi: 10.1200/jco.2013.31.15_suppl.9016